Oncology Speed Read Video overview 

The latest developments in BRAF-mutant and MSI-H mCRC

Expert insights on recent clinical and real-world data

Prof. Chiara Cremolini

Prof. Chiara Cremolini
Publication Date

Jul 2025

info Summary and next episodes download Downloadable resources

Prof. Chiara Cremolini reviews the latest clinical and real-world data in the treatment of BRAF-mutant and MSI-H metastatic colorectal cancer (mCRC), with a particular focus on the following two studies: 

  • BREAKWATER: First-line encorafenib + cetuximab + mFOLFOX6 vs standard of care in BRAFV600E-mutant mCRC 
  • CheckMate 8HW: Nivolumab + ipilimumab vs chemotherapy or nivolumab monotherapy for MSI-H/dMMR mCRC 

Watch the short video for a summary of Professor Cremolini’s perspectives.  Download the slide deck for more details on the data. 

  • Understand clinical trial data and real-world evidence of therapies for the treatment of BRAFV600E-mutant and MSI-H mCRC and relevant patient subgroups 
  • Recognise the appropriate sequencing of therapies for the treatment of BRAFV600E-mutant and MSI-H mCRC across the patient journey to ensure optimal outcomes 

Dr Chiara Cremolini is a Medical Oncologist at Santa Chiara University Hospital in Pisa, Italy. Chiara completed her M.D. Degree in 2008, and gained an M.Sc. in Clinical Trials in 2011, and the Specialty in Medical Oncology in 2014 at the University of Pisa. She is mainly committed to the clinical management of patients affected by gastrointestinal malignancies and is involved in clinical and translational research projects in the field of colorectal oncology. She actively contributes to clinical trials by the cooperative Gruppo Oncologico Nord Ovest (GONO) group and is interested in the identification of molecular predictors of benefit from systemic treatments. Chiara is co-author of about 60 peer-reviewed papers and received merit awards at the following meetings: American Society of Clinical Oncology (ASCO) 2010, 2012−2015; European Society for Medical Oncology (ESMO) 2011 and 2014; European CanCer Organisation (ECCO) 2013.

Prof. Chiara Cremolini has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants for research projects:

Bayer, Merck, Nordic Pharma, Pierre Fabre, Roche, Servier, Takeda, Tempus, 
pdf Download slides - PDF clock
pdf Download slides - PPTX clock

Prof. Chiara Cremolini reviews the latest clinical and real-world data in the treatment of BRAF-mutant and MSI-H metastatic colorectal cancer (mCRC), with a particular focus on the following two studies: 

  • BREAKWATER: First-line encorafenib + cetuximab + mFOLFOX6 vs standard of care in BRAFV600E-mutant mCRC 
  • CheckMate 8HW: Nivolumab + ipilimumab vs chemotherapy or nivolumab monotherapy for MSI-H/dMMR mCRC 

Watch the short video for a summary of Professor Cremolini’s perspectives.  Download the slide deck for more details on the data. 

  • Understand clinical trial data and real-world evidence of therapies for the treatment of BRAFV600E-mutant and MSI-H mCRC and relevant patient subgroups 
  • Recognise the appropriate sequencing of therapies for the treatment of BRAFV600E-mutant and MSI-H mCRC across the patient journey to ensure optimal outcomes 

Dr Chiara Cremolini is a Medical Oncologist at Santa Chiara University Hospital in Pisa, Italy. Chiara completed her M.D. Degree in 2008, and gained an M.Sc. in Clinical Trials in 2011, and the Specialty in Medical Oncology in 2014 at the University of Pisa. She is mainly committed to the clinical management of patients affected by gastrointestinal malignancies and is involved in clinical and translational research projects in the field of colorectal oncology. She actively contributes to clinical trials by the cooperative Gruppo Oncologico Nord Ovest (GONO) group and is interested in the identification of molecular predictors of benefit from systemic treatments. Chiara is co-author of about 60 peer-reviewed papers and received merit awards at the following meetings: American Society of Clinical Oncology (ASCO) 2010, 2012−2015; European Society for Medical Oncology (ESMO) 2011 and 2014; European CanCer Organisation (ECCO) 2013.

Prof. Chiara Cremolini has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants for research projects:

Bayer, Merck, Nordic Pharma, Pierre Fabre, Roche, Servier, Takeda, Tempus, 
pdf Download slides - PDF clock
pdf Download slides - PPTX clock
Programme summary
Watch the video now
Share this programme
x-twitter
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
Supporter Acknowledgement
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe, Pierre Fabre Laboratories, Amgen and AstraZeneca US.  

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories, Thermo Fisher Scientific and Daiichi Sankyo.

Meet the experts
Brought to you by
GI NURSES CONNECT

GI NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved
Programme summary
Share this programme
x-twitter
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
Supporter Acknowledgement
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe, Pierre Fabre Laboratories, Amgen and AstraZeneca US.  

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories, Thermo Fisher Scientific and Daiichi Sankyo.

Meet the experts
Brought to you by
GI NURSES CONNECT

GI NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
NET CONNECT
Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
NET CONNECT
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
conference-update Conference update
Oncology 
Update from ESGO 2026 – PYNNACLE Phase 2 study: Interim results from the ovarian cancer cohort

Clinical insights and expert discussion

Experts
Prof. Domenica Lorusso, Prof. Jean-Sebastien Frenel
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2026
COR2ED
This programme has been sponsored by PMV Pharma and is intended for HCPs only.
publication Scientific Publication
Oncology 
ADCs in HER2+ metastatic breast cancer and management of adverse events

Consensus-based guidance for clinicians and patients

Experts
Prof. Javier Cortés, Prof. Giuseppe Curigliano, Prof. Shaheenah Dawood, Dr Grażyna Suchodolska, Dr Sara Tolaney, Carla Whitbread
Endorsed by
EONS - European Oncology Nursing Society Europa Donna
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Feb 2026
  • Non-accredited Independent Medical Education
BREAST CANCER CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca
expert-video-animation Animated Video
Oncology Obstetrics and Gynecology 
Understanding HER2 testing in gynecological cancers

Best practices and treatment implications

Experts
Prof. Fernando A. Soares
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 8 MIN
  • calendar Feb 2026
  • Non-accredited Independent Medical Education
PRECISION ONCOLOGY CONNECT OBSTETRICS & GYNECOLOGY CONNECT 
Educational programme supported by an Independent Educational Grant from Daiichi Sankyo.
Explore all programmes